Display options
Cite
Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016;2(1):10-9doi: 10.1159/000444206.
Nienhuis, H. L., Bijzet, J., & Hazenberg, B. P. (2016). The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney diseases (Basel, Switzerland), 2(1), 10-9. https://doi.org/10.1159/000444206
Nienhuis, Hans L A, et al. "The Prevalence and Management of Systemic Amyloidosis in Western Countries." Kidney diseases (Basel, Switzerland) vol. 2,1 (2016): 10-9. doi: https://doi.org/10.1159/000444206
Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016 Apr;2(1):10-9. doi: 10.1159/000444206. Epub 2016 Feb 25. PMID: 27536687; PMCID: PMC4946260.
Copy Download .nbib Format: NLM
Share it on

Kidney Dis (Basel). 2016 Apr;2(1):10-9. doi: 10.1159/000444206. Epub 2016 Feb 25.

The Prevalence and Management of Systemic Amyloidosis in Western Countries.

Kidney diseases (Basel, Switzerland)

Hans L A Nienhuis, Johan Bijzet, Bouke P C Hazenberg

Affiliations

  1. Department of Rheumatology & Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

PMID: 27536687 PMCID: PMC4946260 DOI: 10.1159/000444206

Abstract

BACKGROUND: Amyloidosis has been a mystery for centuries, but research of the last decennia has clarified many of the secrets of this group of diseases. A protein-based classification of amyloidosis helps to understand problems that were part of the obsolete clinical classification in primary, secondary, and familial amyloidosis. All types of amyloid are secondary to some underlying precursor-producing process: each type is caused by a misfolded soluble precursor protein that becomes deposited as insoluble amyloid fibrils.

SUMMARY: The incidence of amyloidosis is not well documented, but probably falls between 5 and 13 per million per year. Prevalence data are scarce, but one UK study indicates about 20 per million inhabitants. Amyloidosis can be localized (amyloid deposited in the organ or tissue of precursor production) or systemic (amyloid at one or more sites distant from the site of precursor production). The major systemic types of amyloidosis are AL (associated with a light chain-producing plasma cell dyscrasia), AA (associated with longstanding inflammation), wild-type ATTR (associated with normal transthyretin and old age), and hereditary ATTR (associated with a transthyretin mutation) amyloidosis. Imaging techniques, such as cardiac ultrasound, magnetic resonance imaging, bone scintigraphy, and serum amyloid P component scintigraphy, are useful both for diagnosing amyloidosis and for assessing disease severity. Serologic markers are useful for detecting organ disease and disease monitoring during follow-up. Current treatment modalities are directed against the ongoing supply of precursor proteins and thereby aim to stop further accumulation of amyloid. Novel treatment modalities, such as interference with amyloid formation and even removal of amyloid, are being studied. A well-thought and planned monitoring during follow-up helps to assess the effect of treatment and to early detect possible progression of amyloidosis.

KEY MESSAGES: Clinical management comprises histologic proof of amyloid, evidence of systemic deposition, reliable typing, precursor assessment, severity of organ disease, risk assessment and prognosis, choice of treatment, and planned monitoring during follow-up.

FACTS FROM EAST AND WEST: (1) AL amyloidosis is the most prevalent type of amyloidosis accounting for 65% of the amyloidosis-diagnosed patients in the UK and for 93% of the amyloidosis-diagnosed patients in China. The predisposition of men over women to develop AL amyloidosis might be higher in China than in Western countries (2:1 vs. 1.3:1). Both in the East and West, incidence increases with age. At the time of diagnosis, edema is twice as frequent and the proportion of renal involvement is higher in Chinese compared to Western patients. (2) Melphalan followed by autologous stem cell transplantation (ASCT) is the current standard therapy but is restricted to eligible patients. The efficacy and safety of bortezomib combined with dexamethasone were proven in Western patients and recently confirmed in a Chinese cohort. Recent studies in China and the US indicate that bortezomib induction prior to ASCT increases the response rate. Thalidomide and lenalidomide have shown benefit, but toxicity and lack of clinical evidence exclude these agents from first-line therapy. The green tea extract epigallocatechin-3-gallate is under investigation as an inhibitor of AL amyloid formation and a compound that might dissolve amyloid.

Keywords: Diagnosis; Monitoring; Precursor proteins; Treatment; Typing

References

  1. N Engl J Med. 2013 Aug 29;369(9):819-29 - PubMed
  2. Nephrol Dial Transplant. 2016 Apr;31(4):507-9 - PubMed
  3. Am J Surg Pathol. 2006 Jun;30(6):673-83 - PubMed
  4. Amyloid. 2015 Mar;22(1):19-25 - PubMed
  5. Eur Heart J. 2015 Oct 7;36(38):2585-94 - PubMed
  6. J Clin Oncol. 2012 Dec 20;30(36):4541-9 - PubMed
  7. Circulation. 2015 Oct 20;132(16):1570-9 - PubMed
  8. BMC Med Genet. 2013 Sep 03;14:88 - PubMed
  9. Br J Haematol. 2013 Mar;160(5):582-98 - PubMed
  10. Blood. 2011 Dec 15;118(25):6610-7 - PubMed
  11. Haematologica. 2007 Oct;92(10):1415-8 - PubMed
  12. Am J Med Sci. 1960 Sep;240:332-6 - PubMed
  13. Ann Rheum Dis. 2013 Mar;72 (3):464-5 - PubMed
  14. N Engl J Med. 2007 Jun 7;356(23):2349-60 - PubMed
  15. PLoS One. 2012;7(12 ):e52686 - PubMed
  16. Autoimmun Rev. 2012 Nov;12(1):81-6 - PubMed
  17. Arthritis Rheum. 2006 Jun;54(6):2015-21 - PubMed
  18. N Engl J Med. 2007 Sep 13;357(11):1083-93 - PubMed
  19. J Clin Oncol. 2012 Mar 20;30(9):989-95 - PubMed
  20. Amyloid. 2014 Dec;21(4):221-4 - PubMed
  21. Acta Med Scand. 1971 Nov;190(5):453-4 - PubMed
  22. Gene Ther. 2011 Dec;18(12):1150-6 - PubMed
  23. JAMA. 2013 Dec 25;310(24):2658-67 - PubMed
  24. Amyloid. 2011 Dec;18(4):200-5 - PubMed
  25. Amyloid. 2012 Jun;19 Suppl 1:34-6 - PubMed
  26. Br J Haematol. 2001 Sep;114(3):529-38 - PubMed
  27. J Am Heart Assoc. 2013 Apr 22;2(2):e000098 - PubMed
  28. Eur J Nucl Med Mol Imaging. 2012 Oct;39(10 ):1609-17 - PubMed
  29. Rheum Dis Clin North Am. 2013 May;39(2):323-45 - PubMed
  30. Am J Surg Pathol. 2011 Nov;35(11):1685-90 - PubMed
  31. Haematologica. 2009 Aug;94(8):1094-100 - PubMed
  32. Lancet. 2001 Jul 7;358(9275):24-9 - PubMed
  33. Nature. 2010 Nov 4;468(7320):93-7 - PubMed
  34. JACC Cardiovasc Imaging. 2013 Apr;6(4):488-97 - PubMed
  35. Blood. 2009 Dec 3;114(24):4957-9 - PubMed
  36. Ann Intern Med. 2004 Jan 20;140(2):85-93 - PubMed
  37. Amyloid. 2011 Dec;18(4):177-82 - PubMed
  38. BMC Public Health. 2012 Nov 13;12:974 - PubMed
  39. Blood. 1992 Apr 1;79(7):1817-22 - PubMed
  40. Neurology. 2012 Aug 21;79(8):785-92 - PubMed
  41. Heart Fail Rev. 2015 Mar;20(2):145-54 - PubMed
  42. Arthritis Rheum. 1993 May;36(5):691-7 - PubMed
  43. Clin Res Cardiol. 2012 Oct;101(10):805-13 - PubMed
  44. Am J Hematol. 2005 Aug;79(4):319-28 - PubMed
  45. Neth J Med. 1986;29(11):376-85 - PubMed
  46. Amyloid. 2012 Jun;19 Suppl 1:43-4 - PubMed
  47. Ann Med. 2008;40(3):232-9 - PubMed
  48. Clin Neuroradiol. 2015 Oct;25 Suppl 2:283-9 - PubMed
  49. Transplantation. 2015 Sep;99(9):1847-54 - PubMed
  50. N Engl J Med. 2015 Sep 17;373(12 ):1106-14 - PubMed
  51. Br J Haematol. 2013 May;161(4):525-32 - PubMed
  52. Am J Med. 2006 Apr;119(4):355.e15-24 - PubMed
  53. Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1095-101 - PubMed
  54. J Exp Med. 1969 Oct 1;130(4):777-96 - PubMed

Publication Types